This site is for US Residents only

  • Dosing & Administration


Somatuline Depot is a deep subcutaneous injection NOT an intramuscular (IM) injection1

Somatuline® Depot is delivered into the soft fatty layer of tissue underneath the skin.

Intramuscular (IM) injections3

Intramuscular injections are delivered into the muscles, generally requiring longer needles.

How to use the syringe

Please see Instructions for Use located in the full Prescribing Information for a complete list of administration steps.1
Watch a video about how to use the syringe.

room temperature

DO remove from refrigerator and let sealed pouch sit for 30 minutes to reach room temperature*

DON’T open sealed pouch or inject medication that has not yet reached room temperature; injecting cold medication may be painful for your patient

DO administer deep subcutaneous injection only

DON’T administer medication intramuscularly. If you do, do not administer another dose

DO administer in the upper outer quadrant of the right or left buttock

DON’T administer in the arm, calf, abdomen, or any other part of the body

DO alternate injection sites between appointments

DON’T inject in the same location as the last appointment

DO flatten the area by using your thumb and index finger to spread the skin

DON’T fold, squeeze, or pinch the skin

DO insert needle at a 90 degree angle only, and all the way into the skin (the needle should not be visible)

DON’T aspirate (draw back the plunger) before injecting, or inject at an angle other than 90 degrees

*Product left in its sealed pouch at room temperature (not to exceed 104°F or 40°C) for up to 24 hours may be returned to the refrigerator for continued storage and use at a later time.1

GEP-NET=gastroenteropancreatic neuroendocrine tumor; IM=intramuscular


  • Somatuline Depot (lanreotide) Injection [Prescribing Information]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; February 2023.
  • Giving a Subcutaneous Injection. Bethesda, MD: National Institutes of Health Clinical Center; July 2016.
  • Hopkins U, Arias CY. Large-volume IM injections: a review of best practices. Oncol Nurse Advis. 2013;32-37.



  • SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.

Warnings and Precautions

  • Cholelithiasis and Gallbladder Sludge
    • SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation.
    • Periodic monitoring may be needed.
    • If complications of cholelithiasis are suspected, discontinue SOMATULINE DEPOT and treat appropriately.
  • Hypoglycemia or Hyperglycemia
    • Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.
    • Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
  • Cardiovascular Abnormalities
    • SOMATULINE DEPOT may decrease heart rate.
    • In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia.
    • In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.

Most Common Adverse Reactions

  • GEP-NETs: Adverse reactions in >10% of patients who received SOMATULINE DEPOT were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%).
  • Carcinoid Syndrome: Adverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. Adverse reactions in ≥5% of patients who received SOMATULINE DEPOT and at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%).

Drug Interactions

  • SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed); increase the absorption of bromocriptine; and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).

Special Populations

  • Lactation: Advise women not to breastfeed during treatment and for 6 months after the last dose.

To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127 or FDA at 1-800-FDA-1088 or


  • SOMATULINE® DEPOT (lanreotide) is a somatostatin analog indicated for: the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and
  • the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.